Galectin Therapeutics Inc. (GALT)

[biotech2010]

Earnings reports for a company without revenue are pretty much meaningless, I don't know why anyone would be concerned.

The quarterly report was released this morning, the only interesting point (to me) was the following:

Dr. Traber added, “A large percentage of NASH patients also suffer from psoriasis, possibly because both NASH and psoriasis are diseases with increased galectin-3 activity. Given that GR-MD-02 is a galectin-3 inhibitor, and based on a patient in our Phase 1 safety study showing resolution of her psoriasis for 17 months, we embarked last year on 10-patient Phase 2 open-label clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. We look forward to reporting interim data from this study in the near future.

The annual report had mentioned September for psoriasis data, this is definitely an acceleration of that date.